Cannabis and Hemp Industry Investment News
An Australian fund manager has increased its stake to 19.61% in the company. A number of board and management personnel have been buying shares recent...
What are you searching for? viewCannPal Animal Therapeutics Ltd A number of board members have purchased shares in the company in 2019 to date. The sh...
The company’s research results into cannabinoid treatments for animals have been presented at a leading veterinary conference. Lead drug candidate CPA...
The company will present findings of study into cannabinoid treatment for companion animals at AVA Innovation Symposium next month. The company is foc...
What are you searching for? viewCannPal Animal Therapeutics Ltd This follows chairman Geoff Starr’s on-market share purchases last month. The company ...
This is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well u...
CPAT-01 is CP1’s lead pharmaceutical product and is derived from cannabinoids. CPAT-01’s market is estimated to be worth US$1 billion globally () has ...
What are you searching for? viewCannPal Animal Therapeutics Ltd 80,000 shares at a cost of $10,193 represents a 12.7 cents per share average cost pric...
() intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study o...
Non-executive director Rob Clifford now holds more than 480,000 shares in an indirect interest. The cannabis-derived pain control drug candidate CPAT-...
CannPal’s aim is to be one of the first companies to provide veterinarians with GMP-produced and regulatory approved cannabinoid-derived therapeutics ...
Non-executive director Max Johnston now holds 200,000 shares in an indirect interest. The cannabis-derived pain control drug candidate CPAT-01 is targ...
The company had a healthy cash balance of $4.72 million at the end of the quarter. The company is researching the benefits of medical cannabis for dog...
Non-executive director Max Johnston has acquired shares on-market valued at more than $9,000. The company is developing cannabis-based pharmaceuticals...
CannPal plans to take the results from its recently commenced phase 1A and B studies to file an Investigational New Animal Drug application with the F...
The company will move onto phase II studies after this phase is complete. Shares have rallied to 20 cents recently, up from last month's low of 16.5 c...
A cooperative relationship in the field of veterinary science will be established. The aim is to complete a pilot study targeting epilepsy in dogs in ...
Results from the phase Ib study are expected during this September quarter. The cannabis-derived pain control drug candidate CPAT-01 is targeting cats...
The company's lead drug candidate is a cannabis-derived canine pain medication. The company listed on the ASX in October 2017 via IPO () is leveraged ...
The company has entered into a research services agreement Eurofins Animal Health Pty Ltd. The collaboration will seek to expand the development progr...
